Efficacy and Safety of Ad5FGF-4 for Myocardial Ischemia in Patients With Stable Angina Due to Coronary Artery Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

11 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether a single intracoronary infusion of Ad5FGF-4, delivered during induced transient ischemia, is effective in improving myocardial perfusion, angina functional class, patient symptoms, and quality of life. Short-term (8 weeks) and long-term (12 month) safety of Ad5FGF-4 will also be evaluated. The primary endpoint is change in adenosine triphosphate (ATP) stress SPECT reperfusion defect size.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Adenovirus Vascular Endothelial Growth Factor D (AdvVEGF-D) Therapy for Treatment of Refractory Angina Pectoris

NCT03039751

Refractory Angina Pectoris Gene Transfer Coronary Artery Disease

COMPLETED PHASE2

Safety of TG100-115 for Heart Attack Treated With Angioplasty

NCT00103350

Myocardial Infarction

COMPLETED PHASE1/PHASE2

Phase II Study for the Diagnosis and Functional Assessment of CAD Using Transthoracic-Echodoppler

NCT01593644

Ischemic Heart Disease

UNKNOWN PHASE2

Post Ten Year Follow up Assessment of a Phase I Trial of Angiogenic Gene Therapy

NCT01174095

Coronary Artery Disease Ischemia

COMPLETED

Adenosine's Effect on STunning Resolution in Acute Myocardial Infarction

NCT05014061

Myocardial Ischemia

WITHDRAWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Angina, Stable

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A: Ad5FGF-4

Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer and standard of care angina medication

Group Type EXPERIMENTAL

Alferminogene tadenovec

Intervention Type GENETIC

One-time intracoronary infusion of Ad5FGF-4 (6x10e9 viral particles in buffer)

Arm B

Standard of care angina medication

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Alferminogene tadenovec

One-time intracoronary infusion of Ad5FGF-4 (6x10e9 viral particles in buffer)

Intervention Type GENETIC

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Generx Cardionovo (Russian Trade Name)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients 18-75 years of age, inclusive
* Postmenopausal female patients, women of childbearing potential and men willing to use an effective contraception method while on the study treatment and/or who agree not to become pregnant or make their partner pregnant throughout the study and during one year after administration of the study drug
* Female subjects of childbearing potential who have a negative urine pregnancy test, and are willing to use an acceptable form of birth control during the study
* Diagnostic coronary angiogram in the past confirming the presence of coronary artery disease. Patients with extensive disease, or high risk for intervention, or who don't want the higher risk angioplasty or surgery, or have had angioplasty with recurrent angina and vessels are not ideal for angioplasty are ideal candidates
* Stable angina pectoris being treated with chronic anti-anginal medication(s) at a stable dose for 2 weeks prior to randomization
* Left ventricular ejection fraction (LVEF) of ≥30%. If the LVEF is \<30% the patient can be enrolled if there is no recent or current congestive heart failure present
* Evidence of stress induced myocardial ischemia by ATP technetium-99m sestamibi SPECT, defined as a reversible perfusion defect size of ≥9%
* Willing and able to comply with the study requirements
* Provided written informed consent

Exclusion Criteria

* Female patients who are pregnant, lactating (breast milk feeding), or planning a pregnancy during the course of the study and one year after administration of the study drug. Women of child bearing potential who are not using an acceptable method of birth control. Women of child bearing potential with a positive urine pregnancy test within 24 hours prior to the start of investigational product
* Patients with unstable angina for whom an immediate revascularization procedure is indicated
* Patients for whom a cardiac revascularization procedure is planned in the next 3 months
* Myocardial infarction within the 3 months prior to the Screening visit
* Congestive heart failure NYHA Class IV
* Myocarditis or restrictive pericarditis
* Left main coronary stenosis ≥70% (unless the patient has a patent graft or collateral vessels supplying the left coronary circulation) or proximal stenoses ≥70% in all major coronary conduit vessels (coronary arteries and bypass grafts)
* A single patent coronary conduit (for example, totally occluded RCA and LCx with no bypass grafts. Patient will not tolerate balloon occlusion of the LAD for infusion)
* Clinically significant aortic or mitral valvular heart disease.
* Life threatening coronary ostial stenosis that precludes adequate catheter engagement in any target vessel, unless the vessel can be accessed via a patent bypass graft
* Coronary artery to venous communications, which bypass the coronary capillary bed
* Untreated life-threatening ventricular arrhythmias
* Uncontrolled arterial hypertension with systolic blood pressure \>180 mm Hg and diastolic pressure \>100 mm Hg
* CABG surgery within the past 6 months, unless those grafts are now occluded
* Percutaneous transluminal coronary angioplasty (PTCA) within the past 3 months, unless the stented/dilated vessel(s) are now occluded
* Enhanced external counterpulsation (EECP) within 3 months prior to the start of screening evaluations
* Transmyocardial or percutaneous myocardial laser revascularization within the previous year
* Prior treatment with any cardiovascular gene therapy
* Patients who received an investigational drug or biologic within 30 days of screening or are currently participating in an investigational drug, biologic or device trial

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No